DCTH 株価推移チャート
DCTH 収入
Delcath Systems Inc
$11.46
-1.29%
$-0.14
終値： May 14, 16:00:00 GMT-4
$11.66
1.74%
$0.19
アフターマーケット：May 14, 20:00:00 GMT-4
戻る
Delcath Systems Inc (DCTH) 収入
最新の利益結果: Q4 '25
報告済み: 2026-02-26
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
DCTHの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Delcath Systems Inc DCTHの前四半期の収益はどうでしたか？
Delcath Systems Incの収益見積もりはいくらですか？
Delcath Systems Incの収益品質スコアはどれくらいですか？
Delcath Systems Incはいつ収益を報告しますか？
Delcath Systems Incの予想収益はいくらですか？
Delcath Systems Incは収益予想を上回りましたか？
主要データ
前終値
$11.61
始値
$11.62
当日レンジ
$11.35 - $11.66
52週レンジ
$8.12 - $18.23
取引高
421.1K
平均取引高
430.4K
配当利回り
--
1株当たり利益(TTM)
0.01
時価総額
$401.6M
DCTHとは何ですか？
Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. The company is headquartered in Queensbury, New York and currently employs 156 full-time employees. The company went IPO on 2000-10-19. The firm's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
